Showing results (11-20 of 198) with videos related to
Sort By:
Pageof 20
Expert Review of Hematology|July 28, 2018
New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?Simon Rule, Robert W ChenBlood|November 3, 2018
Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!Martin Dreyling, Wolfram Klapper, Simon RuleLeukemia & Lymphoma|April 26, 2021
Phase I, first-in-human trial of Bruton's tyrosine kinase inhibitor M7583 in patients with B-cell malignanciesWojciech Jurczak, Simon Rule, William Townsend, et al.Expert Review of Hematology|August 28, 2014
Ibrutinib for the treatment of mantle cell lymphomaNimish Shah, Claire Hutchinson, Simon RuleHematology/Oncology Clinics of North America|August 31, 2020
What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?Rory McCulloch, Toby A Eyre, Simon RuleJournal of Medical Economics|April 12, 2014
Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United KingdomSimon Rule, Graham P Collins, Kunal SamantaClinical Lymphoma, Myeloma & Leukemia|November 11, 2017
A Systematic Review of Treatments of Relapsed/Refractory Mantle Cell LymphomaMadeliene Parrott, Simon Rule, Michael Kelleher, et al.Leukemia & Lymphoma|September 13, 2014
How applicable is fludarabine, cyclophosphamide and rituximab to the elderly?Nimish Shah, Constantine Tam, John F Seymour, et al.British Journal of Haematology|October 26, 2012
Abnormal serum free light chain ratio predicts poor overall survival in mantle cell lymphomaMichelle Furtado, Nimish Shah, Alison Levoguer, et al.British Journal of Haematology|August 23, 2014
Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphomaMichelle Furtado, Rod Johnson, Anton Kruger, et al.Pageof 20